# LFST LifeStance Health Group, Inc.

1. [Home](https://finlab.finance/en)
2. [U.S. Stocks](https://finlab.finance/en/stocks/us)
3. LifeStance Health Group, Inc.(LFST)

Healthcare

13.82 USD Close 11/20

Since 2024-12-23 +90.4%

Close 11/20

* Open

  13.21

* High

  13.83

* Low

  13.21

* Prev close

  13.34

* Volume

  5.62M

* Amplitude

  4.65%

* P/E

  76.3

* P/B

  3.5

* Revenue YoY (TTM)

  +22.6%

52W 6.09 15.66

FinLab Studio

From LifeStance Health Group, Inc. to every stock like it

AI finds several complementary traits of LifeStance Health Group, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

[Screen stocks like LifeStance Health Group, Inc.](https://studio.finlab.finance/en/stocks/us/LFST)

## Is LifeStance Health Group, Inc. a buy? Fundamentals and valuation first

As of 2026-11-20

Momentum: Strong, Risk / liquidity: Good; Valuation: Pricey, Growth: Weak.

Valuation Pricey Free-cash-flow yield is Good, but TTM P/E is Expensive.

TTM P/E 76.3 90th percentile · Expensive

Price / book 3.5 78th percentile · Pricey

Free-cash-flow yield (%) 4.1 63th percentile · Good

[US Stock Backtest in Python: Price-to-Book Ratio Strategy](https://finlab.finance/en/blog/us-stock-backtest-price-to-book-strategy)[Quality Factor Investing: A US Quality Value Backtest](https://finlab.finance/en/blog/us-quality-value-strategy)

Quality Neutral FCF margin, TTM is Good, but Operating margin, TTM is Average.

ROE, TTM (%) 4.8 53th percentile · Good

Operating margin, TTM (%) 6.2 48th percentile · Average

FCF margin, TTM (%) 12.8 67th percentile · Good

[Quality Factor Investing: A US Quality Value Backtest](https://finlab.finance/en/blog/us-quality-value-strategy)

Growth Weak Revenue growth, TTM YoY is Good, but Diluted EPS growth, TTM YoY is Lagging.

Revenue growth, TTM YoY (%) 22.6 76th percentile · Good

Diluted EPS growth, TTM YoY (%) -861.3 3th percentile · Lagging

Momentum Strong All 2 indicators are Top.

60-day return (%) 12.4 94th percentile · Top

240-day return (%) 115.6 98th percentile · Top

[Momentum Trading Strategy: A 12-1 Momentum Backtest](https://finlab.finance/en/blog/us-momentum-strategy)

Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.

20-day dollar volume 101,141,514.0 87th percentile · Top

60-day annualized volatility (%) 36.9 38th percentile · Good

[Factor Investing Explained: 10 Classic Factors in US Stocks](https://finlab.finance/en/blog/us-factor-investing)

## LifeStance Health Group, Inc. (LFST) today

2 quant signals active · As of 2026-11-20

* Signal [Top-quintile 6-month momentum 8 events · 60-day win rate 37.5% · +0.71 pp vs market](https://finlab.finance/en/stocks/us/LFST#mom_lead "The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.")

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

[Overview](https://finlab.finance/en/stocks/us/LFST#zone-position)[Peers](https://finlab.finance/en/stocks/us/LFST#zone-peers)[Signal backtests](https://finlab.finance/en/stocks/us/LFST#zone-evidence)

## LifeStance Health Group, Inc. (LFST) peers and tracking

Watchlist

This page refreshes daily after the close. Add LifeStance Health Group, Inc. to your watchlist to track signal changes on your next visit.

## LifeStance Health Group, Inc. (LFST) quant signal backtests

### Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S\&P 500.

### Top-quintile 6-month momentum

Active · now 98.7%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

[Momentum Trading Strategy: A 12-1 Momentum Backtest](https://finlab.finance/en/blog/us-momentum-strategy)

8 historical occurrences (since 2022-11-01)

Average forward return after Top-quintile 6-month momentum

20-day: Win 50.0%, Sample 8, Median +0.9%, Excess -3.8%, Beat mkt rate 50.0%

60-day: Win 37.5%, Sample 8, Median -4.5%, Excess +0.7%, Beat mkt rate 37.5%

120-day: Win 57.1%, Sample 7, Median +1.7%, Excess +4.0%, Beat mkt rate 42.9%

120 days after: historical avg +10.2%

20-day -3.3%

60-day +2.7%

120-day +10.2%

20-day

60-day

120-day

Win

50.0%

37.5%

57.1%

Sample

8

8

7

Median

+0.9%

-4.5%

+1.7%

Excess

-3.8%

+0.7%

+4.0%

Beat mkt rate

50.0%

37.5%

42.9%

Over 7 occurrences, 120-day forward avg gained 10.2%, beat the market by 4.0 pts; win rate 57.1%.

### Filed revenue acceleration

Active · now 22.6%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

5 historical occurrences (since 2024-02-28)

More history: Market-wide momentum baseline, Signals not active now

### Market-wide momentum baseline

> Across 101,580 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.21%, a 58.5% positive-return rate, and +2.90 percentage points of average excess return versus the S\&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S\&P 500 (^GSPC).

### Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

### 52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

### EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

[PEAD: Post-Earnings Announcement Drift Backtest](https://finlab.finance/en/blog/us-earnings-surprise-strategy)

14 times historically; 60-day forward avg -1.1%, win rate 61.5%, beating the market by -5.5 pts on average.

## Method and limits

* Returns use us\_price:adj\_close, adjusted for splits and dividends where available.
* Excess returns use world\_index:^GSPC as the S\&P 500 benchmark proxy.
* Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
* The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
* Snapshot-only tables such as analyst consensus, DCF, us\_ratios, and us\_key\_metrics are intentionally excluded from historical evidence.
* Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.

Further reading

Browse more quantitative analysis in [U.S. Stocks](https://finlab.finance/en/stocks/us). To turn these signals into backtestable rules, read the [Quantitative Trading Guide](https://finlab.finance/en/tools/quant-trading). Definitions of the Sharpe ratio, drawdown and other quant terms are in the [Quant Glossary](https://finlab.finance/en/glossary). Calculate this stock's risk-adjusted return with the [Sharpe Ratio Calculator](https://finlab.finance/en/tools/sharpe-ratio), and to automate the signals read the [Program Trading Guide](https://finlab.finance/en/tools/program-trading).

[Stock](https://finlab.finance/en/stocks/us/LFST)

Source: https://finlab.finance/en/stocks/us/LFST | Data dates: ../2026-11-20
